Glioblastoma is the most common and aggressive type of primary brain tumor, with an average survival rate of 15 months, ...

In a small but important Phase 1 study, MTX110 is outperforming historic norms of progression free and overall survival ...

The agent is currently being evaluated in a phase 1a study, and a phase 1b/2a study will continue to assess LP-184’s safety ...

A recent study has revealed that chloride flow through channels on the surface of tumor cell lines plays a crucial role in ...

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and ...

Glioblastoma Treatment Drugs MarketThe glioblastoma treatment drugs market is poised for substantial growth, with a projected valuation of approximately USD 756.1 million in 2023. The market is ...

Glioblastoma is the most common – and the most malignant – primary brain tumour in adults. It's aggressive and incurable.

Shilpa Medicare's drug is presently undergoing a Phase 1A clinical trial to test its safety and how well it is tolerated in ...

Glioblastoma, a rare but devastating form of brain cancer, has long been considered virtually incurable. With a grim ...

For patients with glioblastoma imaged daily with magnetic resonance imaging (MRI)-linear accelerator (linac) throughout the ...

Glioblastomas are aggressive brain tumors with a median survival time of less than 22 months despite standard therapy ...

Reagan Newton, known to her family as a sassy, caring, and loving sister and daughter has been receiving treatment for ...